Evaluating short-term biomarkers for heart failure prognosis after hospital discharge
Prognostic Value Of Short-Term Follow-up Biomarkers After Discharge In hOspitalized Patients With Acute Heart Failure
This study is testing if certain blood markers can help predict how well patients with heart failure will do after they leave the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wonju Severance Christian Hospital Academic / other |
| Locations | 1 site (Wŏnju, Gangwondo) |
| Trial ID | NCT04437628 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prognostic value of various surrogate biomarkers, such as natriuretic peptides and growth differentiation factor-15, in hospitalized patients with acute heart failure. By monitoring these biomarkers during short-term follow-up after discharge, the study seeks to determine their effectiveness in predicting clinical outcomes. The research focuses on both heart failure with reduced and preserved ejection fractions, providing insights into the potential for improved patient management post-discharge.
Who should consider this trial
Good fit: Ideal candidates include hospitalized patients diagnosed with acute heart failure, either with reduced or preserved ejection fraction.
Not a fit: Patients with severe conditions limiting life expectancy to less than three months or those unable to be contacted post-study may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict patient outcomes and improve management strategies for those recovering from acute heart failure.
How similar studies have performed: While there is existing research on biomarkers in heart failure, this specific focus on short-term follow-up post-discharge is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: the diagnosis of Heart failure requires the following 1. heart failure with reduced ejection fraction ( A 'reduced' ejection fraction (EF) defined as EF \<40%): the presence of symptoms and/or signs of HF 2. heart failure with preserved ejection fraction ( A 'preserved' EF defined as EF≥ 40%) requires the all of the followings: a) the presence of symptoms and/or signs of HF b) elevated levels of natriuretic peptides (defined as B-type natriuretic peptide (BNP) \>100pg/ml and/or N terminal B-type natriuretic peptide (NT-proBNP) \>300pg/ml) c) any structural heart disease (left atrial volume index ≥ 34 mL/m2, left atrial dimension ≥ 50 mm, posterior or septal wall thickness ≥ 11mm) Exclusion Criteria: * any severe condition limiting life less than 3 months * the patient is not ready to contact by telephone at the end of the study
Where this trial is running
Wŏnju, Gangwondo
- Yonsei University Wonju College of Medicine — Wŏnju, Gangwondo, South Korea (Recruiting)
Study contacts
- Principal investigator: Byung-Su Yoo, MD, PhD — Wonju College of Medicine, Yonsei University
- Study coordinator: Dong-Hyuk Cho, MD, PhD
- Email: why012@gmail.com
- Phone: 82-33-741-0916
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.